Workflow
国际医学(000516) - 2025 Q3 - 季度财报
IMICIMIC(SZ:000516)2025-10-29 09:15

Financial Performance - The company's operating revenue for Q3 2025 was ¥961,129,633.01, a decrease of 18.95% compared to the same period last year[5]. - The net profit attributable to shareholders was -¥128,694,712.92, representing a decline of 234.24% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥122,578,844.09, down 52.03% from the previous year[5]. - Total operating revenue for the period was CNY 2,995,437,323.47, a decrease of 16.9% compared to CNY 3,606,256,924.42 in the previous period[17]. - The company reported a net loss of CNY 273,684,991.31, compared to a profit of CNY 19,971,552.10 in the previous period[15]. - The net profit for the current period is -374,029,115.97, compared to -294,272,771.90 in the previous period, indicating a decline of approximately 27.1%[18]. - Operating profit for the current period is -360,502,200.22, worsening from -283,406,415.63 in the previous period, reflecting a decline of about 27.2%[18]. - The total comprehensive income attributable to the parent company is -293,656,543.41, compared to -212,108,983.83 in the previous period, reflecting a decline of approximately 38.4%[19]. Cash Flow and Assets - Cash flow from operating activities for the year-to-date increased by 47.67%, totaling ¥921,003,855.55[5]. - The company's cash and cash equivalents decreased to CNY 331,072,769.68 from CNY 590,562,003.38, representing a decline of 43.9%[13]. - Cash and cash equivalents at the end of the period decreased to 243,072,769.68 from 427,482,946.42, a decline of about 43.1%[22]. - Investment activities generated a net cash outflow of -147,160,133.41, improving from -406,156,113.17 in the previous period[22]. - Total assets at the end of the reporting period were ¥9,790,656,512.89, a decrease of 7.95% from the end of the previous year[5]. - Total assets decreased to CNY 9,790,656,512.89 from CNY 10,636,321,992.89, reflecting a decline of 7.9%[15]. - Total liabilities decreased to CNY 6,736,386,171.04 from CNY 7,164,331,951.87, a decrease of 6.0%[15]. - The company's equity attributable to shareholders decreased to CNY 3,337,580,628.58 from CNY 3,674,927,755.19, a decline of 9.2%[15]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 103,208[10]. - The largest shareholder, Shaanxi Century New Yuan Commercial Management Co., Ltd., held 27.52% of the shares, amounting to 616,061,198 shares[10]. Expenses - Sales expenses increased by 78.56% year-to-date, primarily due to increased promotional costs[8]. - Research and development expenses rose to 6,045,483.10 from 5,715,774.18, an increase of approximately 5.8%[18]. - Financial expenses decreased to 111,183,899.06 from 130,194,846.46, a reduction of about 14.6%[18]. Earnings Per Share - The company's basic and diluted earnings per share were both -¥0.0572, a decrease of 207.53% year-on-year[5]. - The basic and diluted earnings per share for the current period are both -0.1302, compared to -0.0954 in the previous period, indicating a decline of approximately 36.6%[19].